Neodopaston combination tablets L100 (YJ code: 1169101F1120, standard: 1 tablet) are manufactured by Ohara Pharmaceutical. This medication combines levodopa, converted to dopamine in the brain, and carbidopa, which prevents levodopa’s peripheral breakdown, to treat Parkinson’s disease and parkinsonian syndrome.
Neodopaston combination tablets L100
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →More with the same ingredient
